Free · no account · quoted from the filing

What changed in BMY's 10-Q

Source: 10-Q filed 2026-04-30 · compared against 10-Q 2025-10-30. Every passage below is quoted verbatim from the filing itself.

Tariffs / Government actions

This filing

BMS will receive certain U.S. tariff relief until January 2029, including for recently imposed tariffs relating to patented pharmaceuticals... and will not be subject to future pricing mandates in the U.S.

Gross-to-net adjustments

This filing

GTN adjustments percentage 34 % 45 % (11) %

Revenue composition

This filing

U.S. revenues decreased 1% during the first quarter of 2026

Operating cash flow

This filing

Net cash provided by operating activities 1,104 1,954

Legacy portfolio erosion

This filing

Revlimid 349 936

R&D and impairment charges

This filing

Impairment charges 412 5

What it means — the analyst reading

The passages above are the company's own words. The plain-English reading of them — what changed, why it matters, and the direction of travel — is part of the Filing Change Monitor.

See the Filing Change Monitor →

Compared from narrative excerpts (outlook, risks, MD&A) of both filings — quotes are verbatim from the new filing. Not advice. Source: company SEC filings via stockportfolio.pro. Educational, not investment advice.